

PATENT TERM EXTENSION AND NEW PATENTS -April 4, 2003  
 DOCKET NUMBER \*95S-0117  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020899 001	ALBUMIN HUMAN;OPTISON	5573751	APR 25, 2012		
>ADD>			5529766	JUN 25, 2013	U-505	
>ADD>			5558094	FEB 28, 2012	U-505	
	021434 001	ALPRAZOLAM;XANAX XR			NDF	JAN 17, 2006
	021434 002	ALPRAZOLAM;XANAX XR			NDF	JAN 17, 2006
	021434 003	ALPRAZOLAM;XANAX XR			NDF	JAN 17, 2006
	021434 004	ALPRAZOLAM;XANAX XR			NDF	JAN 17, 2006
	020221 002	AMIFOSTINE;ETHYOL	5424471	JUL 31, 2012		
	020965 001	AMINOLEVULINIC ACID HYDROCHLORIDE;LEVULAN	5954703	OCT 31, 2017	U-289	
	021303 001	AMPHETAMINE ASPARTATE;ADDERALL XR 10	6322819	OCT 21, 2018		
	021303 006	AMPHETAMINE ASPARTATE;ADDERALL XR 15	6322819	OCT 21, 2018		
	021303 002	AMPHETAMINE ASPARTATE;ADDERALL XR 20	6322819	OCT 21, 2018		
	021303 004	AMPHETAMINE ASPARTATE;ADDERALL XR 25	6322819	OCT 21, 2018		
	021303 003	AMPHETAMINE ASPARTATE;ADDERALL XR 30	6322819	OCT 21, 2018		
	021303 005	AMPHETAMINE ASPARTATE;ADDERALL XR 5	6322819	OCT 21, 2018		
>ADD>	040422 005	AMPHETAMINE ASPARTATE;DEXTROAMP SACCHARATE			PC	SEP 15, 2003
>ADD>	040422 006	AMPHETAMINE ASPARTATE;DEXTROAMP SACCHARATE			PC	SEP 15, 2003
>ADD>	040422 007	AMPHETAMINE ASPARTATE;DEXTROAMP SACCHARATE			PC	SEP 15, 2003
	021436 001	ARIPIPRAZOLE;ABILIFY	4734416	MAR 29, 2005		
			5006528	OCT 20, 2009		
	021436 002	ARIPIPRAZOLE;ABILIFY	4734416	MAR 29, 2005		
			5006528	OCT 20, 2009		
	021436 003	ARIPIPRAZOLE;ABILIFY	4734416	MAR 29, 2005		
			5006528	OCT 20, 2009		
	021436 004	ARIPIPRAZOLE;ABILIFY	4734416	MAR 29, 2005		
			5006528	OCT 20, 2009		
	021436 005	ARIPIPRAZOLE;ABILIFY	4734416	MAR 29, 2005		
			5006528	OCT 20, 2009		
	021436 006	ARIPIPRAZOLE;ABILIFY	4734416	MAR 29, 2005		
			5006528	OCT 20, 2009		
	021411 001	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590	JAN 11, 2015	U-494 NCE	NOV 26, 2007
			5658590*PED	JUL 11, 2015	U-494 PED	MAY 26, 2008
	021411 002	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590	JAN 11, 2015	U-494 NCE	NOV 26, 2007
			5658590*PED	JUL 11, 2015	U-494 PED	MAY 26, 2008
	021411 003	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590	JAN 11, 2015	U-494 NCE	NOV 26, 2007
			5658590*PED	JUL 11, 2015	U-494 PED	MAY 26, 2008
	021411 004	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590	JAN 11, 2015	U-494 NCE	NOV 26, 2007
			5658590*PED	JUL 11, 2015	U-494 PED	MAY 26, 2008
	021411 005	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590	JAN 11, 2015	U-494 NCE	NOV 26, 2007
			5658590*PED	JUL 11, 2015	U-494 PED	MAY 26, 2008
	021411 006	ATOMOXETINE HYDROCHLORIDE;STRATTERA	5658590	JAN 11, 2015	U-494 NCE	NOV 26, 2007
			5658590*PED	JUL 11, 2015	U-494 PED	MAY 26, 2008
>ADD>	075766 001	CALCITRIOL;CALCITRIOL			PC	SEP 17, 2003
>ADD>	075766 002	CALCITRIOL;CALCITRIOL			PC	SEP 17, 2003

PATENT TERM EXTENSION AND NEW PATENTS -April 4, 2003  
 DOCKET NUMBER \*95S-0117  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	075836 001	CALCITRIOL;CALCITRIOL			PC	SEP 17, 2003
>ADD>	075836 002	CALCITRIOL;CALCITRIOL			PC	SEP 17, 2003
	020637 001	CARMUSTINE;GLIADEL	4789724	AUG 01, 2006	I-382	FEB 25, 2006
			4757128	AUG 01, 2006		
	021150 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC-D 12 HOUR	4525358	JUN 25, 2007	U-295	
			4525358*PED	DEC 25, 2007	U-295	
			6469009	JUL 13, 2019	U-295	
			6469009*PED	JAN 13, 2020	U-295	
			6489329	APR 08, 2016		
			6489329*PED	OCT 08, 2016		
	021473 001	CIPROFLOXACIN;CIPRO XR			NDF	DEC 13, 2005
	020839 001	CLOPIDOGREL BISULFATE;PLAVIX	6504030	JUN 10, 2019		
	019758 001	CLOZAPINE;CLOZARIL			I-380	DEC 18, 2005
	019758 002	CLOZAPINE;CLOZARIL			I-380	DEC 18, 2005
>ADD>	021141 001	COLESEVELAM HYDROCHLORIDE;WELCHOL	6066678	JUN 10, 2014	U-323	
>ADD>	017821 001	CYCLOBENZAPRINE HYDROCHLORIDE;FLEXERIL			D-78	FEB 03, 2006
	021165 001	DESLORATADINE;CLARINEX	4659716	APR 21, 2004	U-427	DEC 21, 2006
			4863931	SEP 15, 2008	PED	JUN 21, 2007
			4804666	FEB 14, 2006	U-428	
			5595997	DEC 30, 2014	U-429	
			6100274	JUL 07, 2019		
			4659716*PED	OCT 21, 2004	U-427	
			4804666*PED	AUG 14, 2006	U-428	
			4863931*PED	MAR 15, 2009		
			5595997*PED	JUN 30, 2015	U-429	
			6100274*PED	JAN 07, 2020		
	021312 001	DESLORATADINE;CLARINEX			NCE	DEC 21, 2006
					PED	JUN 21, 2007
	020401 006	DILTIAZEM HYDROCHLORIDE;TIAZAC	5529791	JUN 25, 2013		
	021168 001	DIVALPROEX SODIUM;DEPAKOTE ER	6511678	DEC 18, 2018		
	021168 002	DIVALPROEX SODIUM;DEPAKOTE ER	6511678	DEC 18, 2018		
	021360 001	EFAVIRENZ;SUSTIVA	5663169	SEP 02, 2014		
>ADD>	021481 001	ENFUVIRTIDE;FUZEON			NCE	MAR 13, 2008
>ADD>	021437 001	EPLERENONE; INSPRA	6534093	DEC 08, 2019	U-3	
>ADD>	021437 002	EPLERENONE; INSPRA	6534093	DEC 08, 2019	U-3	
>ADD>	021437 003	EPLERENONE; INSPRA	6534093	DEC 08, 2019	U-3	
>ADD>	021367 001	ESTRADIOL ACETATE;FEMRING			NP	MAR 20, 2006
>ADD>	021367 002	ESTRADIOL ACETATE;FEMRING			NP	MAR 20, 2006
>ADD>	020747 001	FENTANYL CITRATE;ACTIQ	4863737	SEP 05, 2006		
>ADD>			5785989	SEP 05, 2006		
>ADD>	020747 002	FENTANYL CITRATE;ACTIQ	4863737	SEP 05, 2006		
>ADD>			5785989	SEP 05, 2006		
>ADD>	020747 003	FENTANYL CITRATE;ACTIQ	4863737	SEP 05, 2006		
>ADD>			5785989	SEP 05, 2006		

PATENT TERM EXTENSION AND NEW PATENTS -April 4, 2003  
 DOCKET NUMBER \*95S-0117  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020747 004	FENTANYL CITRATE;ACTIQ	4863737	SEP 05, 2006		
>ADD>	020747 005	FENTANYL CITRATE;ACTIQ	5785989	SEP 05, 2006		
>ADD>	020747 006	FENTANYL CITRATE;ACTIQ	4863737	SEP 05, 2006		
>ADD>	019813 001	FENTANYL;DURAGESIC	4863737	SEP 05, 2006		
	019813 001	FENTANYL;DURAGESIC	5785989	SEP 05, 2006		
	019813 002	FENTANYL;DURAGESIC	4588580	JUL 23, 2004	U-43	
	019813 002	FENTANYL;DURAGESIC	4588580*PED	JAN 23, 2005	U-43	
	019813 003	FENTANYL;DURAGESIC	4588580	JUL 23, 2004	U-43	
	019813 003	FENTANYL;DURAGESIC	4588580*PED	JAN 23, 2005	U-43	
	019813 004	FENTANYL;DURAGESIC	4588580	JUL 23, 2004	U-43	
	019813 004	FENTANYL;DURAGESIC	4588580*PED	JAN 23, 2005	U-43	
	020625 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U-192	
			5855912	FEB 28, 2015		
			5738872	FEB 28, 2015		
			5932247	FEB 28, 2015		
			6037353	MAR 14, 2017	U-138	
			6113942	FEB 28, 2015		
			6187791	MAY 11, 2012	U-138	
			6399632	MAY 11, 2012	U-468	
			5578610*PED	MAY 26, 2014	U-192	
			5738872*PED	AUG 28, 2015		
			5855912*PED	AUG 28, 2015		
			5932247*PED	AUG 28, 2015		
			6037353*PED	SEP 14, 2017	U-138	
			6113942*PED	AUG 28, 2015		
			6187791*PED	NOV 11, 2012	U-138	
			6399632*PED	NOV 11, 2012	U-468	
	020872 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U-139	NDF FEB 25, 2003
			5932247	FEB 28, 2015	PED	AUG 25, 2003
			5855912	FEB 28, 2015		
			6037353	MAR 14, 2017	U-138	
			6113942	FEB 28, 2015		
			6187791	MAY 11, 2012	U-138	
			6399632	MAY 11, 2012	U-468	
			5578610*PED	MAY 26, 2014	U-139	
			5855912*PED	AUG 28, 2015		
			5932247*PED	AUG 28, 2015		
			6037353*PED	SEP 14, 2017	U-138	
			6113942*PED	AUG 28, 2015		
			6187791*PED	NOV 11, 2012	U-138	
			6399632*PED	NOV 11, 2012	U-468	

PATENT TERM EXTENSION AND NEW PATENTS -April 4, 2003  
 DOCKET NUMBER \*95S-0117  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020872 002	FEXOFENADINE HYDROCHLORIDE; ALLEGRA	5578610	NOV 26, 2013	U-139	NDF	FEB 25, 2003
		5932247	FEB 28, 2015		PED	AUG 25, 2003
		5855912	FEB 28, 2015			
		6037353	MAR 14, 2017	U-138		
		6113942	FEB 28, 2015			
		6187791	MAY 11, 2012	U-138		
		6399632	MAY 11, 2012	U-468		
		5578610*PED	MAY 26, 2014	U-139		
		5855912*PED	AUG 28, 2015			
		5932247*PED	AUG 28, 2015			
		6037353*PED	SEP 14, 2017	U-138		
		6113942*PED	AUG 28, 2015			
		6187791*PED	NOV 11, 2012	U-138		
		6399632*PED	NOV 11, 2012	U-468		
		020872 004	FEXOFENADINE HYDROCHLORIDE; ALLEGRA	5578610	NOV 26, 2013	U-139
5932247	FEB 28, 2015				PED	AUG 25, 2003
5855912	FEB 28, 2015					
6037353	MAR 14, 2017			U-138		
6113942	FEB 28, 2015					
6187791	MAY 11, 2012			U-138		
6399632	MAY 11, 2012			U-468		
5578610*PED	MAY 26, 2014			U-139		
5855912*PED	AUG 28, 2015					
5932247*PED	AUG 28, 2015					
6037353*PED	SEP 14, 2017			U-138		
6113942*PED	AUG 28, 2015					
6187791*PED	NOV 11, 2012			U-138		
6399632*PED	NOV 11, 2012			U-468		
020786 001	FEXOFENADINE HYDROCHLORIDE; ALLEGRA-D			5578610	NOV 26, 2013	
		5855912	FEB 28, 2015			
		6037353	MAR 14, 2017	U-138		
		6039974	JUL 31, 2018			
		6113942	FEB 28, 2015			
		6187791	MAY 11, 2012	U-138		
		6399632	MAY 11, 2012	U-468		
		5578610*PED	MAY 26, 2014			
		5855912*PED	AUG 28, 2015			
		6037353*PED	SEP 14, 2017	U-138		
		6039974*PED	JAN 31, 2019			
		6113942*PED	AUG 28, 2015			
		6187791*PED	NOV 11, 2012	U-138		
		6399632*PED	NOV 11, 2012	U-468		
		4357324	FEB 24, 2003			
4357324*PED	AUG 24, 2003					
>ADD>	020038 001	FLUDARABINE PHOSPHATE; FLUDARA				
>ADD>						

PATENT TERM EXTENSION AND NEW PATENTS -April 4, 2003  
 DOCKET NUMBER \*95S-0117  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020101 001	FLUOXETINE HYDROCHLORIDE;PROZAC				NPP	JAN 03, 2006
020974 001	FLUOXETINE HYDROCHLORIDE;PROZAC				PED	JUL 03, 2006
020974 002	FLUOXETINE HYDROCHLORIDE;PROZAC				NPP	JAN 03, 2006
					PED	JUL 03, 2006
>ADD> 021077 001	FLUTICASONE PROPIONATE;ADVAIR DISKUS 100/50	4335121*PED	MAY 14, 2004		NC	AUG 24, 2003
		4335121	NOV 14, 2003		PED	FEB 24, 2004
		5270305	SEP 07, 2010	U-387		
		4992474	FEB 12, 2008	U-211		
		4992474*PED	AUG 12, 2008	U-211		
		5225445*PED	AUG 12, 2008	U-211		
		5290815*PED	SEP 01, 2011	U-396		
		5270305*PED	MAR 07, 2011	U-387		
		5126375*PED	AUG 12, 2008			
		5225445	FEB 12, 2008	U-211		
		5126375	FEB 12, 2008			
		5290815	MAR 01, 2011	U-386		
021077 002	FLUTICASONE PROPIONATE;ADVAIR DISKUS 250/50	4335121	NOV 14, 2003		NC	AUG 24, 2003
		5270305	SEP 07, 2010	U-387	PED	FEB 24, 2004
		4992474	FEB 12, 2008	U-211		
		5225445	FEB 12, 2008	U-211		
		5126375	FEB 12, 2008			
		5290815	MAR 01, 2011	U-386		
		4335121*PED	MAY 14, 2004			
		4992474*PED	AUG 12, 2008	U-211		
		5126375*PED	AUG 12, 2008			
		5225445*PED	AUG 12, 2008	U-211		
		5270305*PED	MAR 07, 2011	U-387		
		5290815*PED	SEP 01, 2011	U-386		
021077 003	FLUTICASONE PROPIONATE;ADVAIR DISKUS 500/50	4335121	NOV 14, 2003		NC	AUG 24, 2003
		5270305	SEP 07, 2010	U-387	PED	FEB 24, 2004
		4992474	FEB 12, 2008	U-211		
		5225445	FEB 12, 2008	U-211		
		5126375	FEB 12, 2008			
		5290815	MAR 01, 2011	U-386		
		4335121*PED	MAY 14, 2004			
		4992474*PED	AUG 12, 2008	U-211		
		5126375*PED	AUG 12, 2008			
		5225445*PED	AUG 12, 2008	U-211		
		5270305*PED	MAR 07, 2011	U-387		
		5290815*PED	SEP 01, 2011	U-386		
019957 001	FLUTICASONE PROPIONATE;CUTIVATE	4335121	NOV 14, 2003			
		4335121*PED	MAY 14, 2004			

PATENT TERM EXTENSION AND NEW PATENTS -April 4, 2003  
 DOCKET NUMBER \*95S-0117  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019958 001	FLUTICASONE PROPIONATE;CUTIVATE	4335121	NOV 14, 2003			
		4335121*PED	MAY 14, 2004			
020121 001	FLUTICASONE PROPIONATE;FLONASE	4335121	NOV 14, 2003		D-76	MAY 23, 2005
		4335121*PED	MAY 14, 2004		PED	NOV 23, 2005
020548 001	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003			
		4335121*PED	MAY 14, 2004			
020548 002	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003			
		4335121*PED	MAY 14, 2004			
020548 003	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003			
		4335121*PED	MAY 14, 2004			
020549 001	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003	U-409		
		4335121*PED	MAY 14, 2004	U-409		
020549 002	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003	U-409		
		4335121*PED	MAY 14, 2004	U-409		
020549 003	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003	U-409		
		4335121*PED	MAY 14, 2004	U-409		
020833 001	FLUTICASONE PROPIONATE;FLOVENT DISKUS 50	4335121	NOV 14, 2003	U-409		
		4335121*PED	MAY 14, 2004	U-409		
020833 002	FLUTICASONE PROPIONATE;FLOVENT DISKUS 100	4335121	NOV 14, 2003	U-409		
		4335121*PED	MAY 14, 2004	U-409		
020833 003	FLUTICASONE PROPIONATE;FLOVENT DISKUS 250	4335121	NOV 14, 2003	U-409		
		4335121*PED	MAY 14, 2004	U-409		
020261 001	FLUVASTATIN SODIUM;LESCOL	5354772	OCT 11, 2011	U-109		
		5354772	OCT 11, 2011	U-413		
020261 002	FLUVASTATIN SODIUM;LESCOL	5354772	OCT 11, 2011	U-109		
		5354772	OCT 11, 2011	U-413		
021192 001	FLUVASTATIN SODIUM;LESCOL XL	5354772	OCT 11, 2011	U-413		
		5354772	OCT 11, 2011	U-109		
020831 001	FORMOTEROL FUMARATE;FORADIL	6488027	MAR 08, 2019			
019915 002	FOSINOPRIL SODIUM;MONOPRIL	4337201	DEC 04, 2002			
		5006344	JUL 10, 2009			
		5006344*PED	JAN 10, 2010			
019915 003	FOSINOPRIL SODIUM;MONOPRIL	4337201*PED	JUN 04, 2003			
		4337201	DEC 04, 2002			
		5006344	JUL 10, 2009			
		5006344*PED	JAN 10, 2010			
019915 004	FOSINOPRIL SODIUM;MONOPRIL	4337201*PED	JUN 04, 2003			
		4337201	DEC 04, 2002			
		5006344	JUL 10, 2009			
		5006344*PED	JAN 10, 2010			
020286 001	FOSINOPRIL SODIUM;MONOPRIL-HCT	4337201*PED	JUN 04, 2003			
		4337201	DEC 04, 2002			
		5006344	JUL 10, 2009			
		5006344*PED	JAN 10, 2010			
		4337201*PED	JUN 04, 2003			

PATENT TERM EXTENSION AND NEW PATENTS -April 4, 2003  
 DOCKET NUMBER \*95S-0117  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020286 002	FOSINOPRIL SODIUM;MONOPRIL-HCT	4337201	DEC 04, 2002			
		5006344	JUL 10, 2009			
		5006344*PED	JAN 10, 2010			
		4337201*PED	JUN 04, 2003			
>ADD>	021282 002	6372252	APR 28, 2020	U-489		
	021321 001	6248726	JUN 19, 2018	U-495		
		4761237	AUG 02, 2005	U-495		
		4886789	DEC 12, 2006	U-495		
		6077836	JUN 20, 2017	U-495		
	021425 001	4364921	MAR 06, 2005	U-498		
	021425 002	4364921	MAR 06, 2005	U-498		
	020857 001	5047407*PED	MAY 17, 2010			
		5047407	NOV 17, 2009			
	021003 001	5047407	NOV 17, 2009			
		5047407*PED	MAY 17, 2010			
	021004 001	5047407	NOV 17, 2009			
		5047407*PED	MAY 17, 2010			
>ADD>	021488 001				NP	FEB 13, 2006
	021130 001				NPP	DEC 19, 2005
	021130 002				NPP	DEC 19, 2005
	021131 001				NPP	DEC 19, 2005
	021132 001				NPP	DEC 19, 2005
	021226 001					
	021226 001	6521651	NOV 01, 2017			
>ADD>	075209 001				PC	JUL 21, 2003
>ADD>	076050 001				PC	JUL 30, 2003
	020386 001	5210079	MAY 11, 2010	U-496	I-383	SEP 17, 2005
	020386 002	5210079	MAY 11, 2010	U-496	I-383	SEP 17, 2005
	020386 003	5210079	MAY 11, 2010	U-496	I-383	SEP 17, 2005
	021410 001				NCE	MAY 25, 2004
	021410 002				NCE	MAY 25, 2004
	021410 003				NCE	MAY 25, 2004
	076119 001				PC	JUN 16, 2003
	076119 002				PC	JUN 16, 2003
	019921 001	4382892	SEP 02, 2003		ODE	MAY 22, 2003
		4551456	NOV 14, 2003	U-80	PED	NOV 22, 2003
		4382892*PED	MAR 02, 2004			
		4551456*PED	MAY 14, 2004	U-80		
>ADD>	021286 002	5616599	APR 01, 2014	U-500		
>ADD>	021286 001	5616599	APR 01, 2014	U-500		
>ADD>	021286 003	5616599	APR 01, 2014	U-500		
>ADD>	020007 003	4695578	JAN 25, 2005			
>ADD>		4753789	JUN 24, 2006	U-44		
	020776 001	6030643	MAY 16, 2017	U-497		
>ADD>	020629 001	6469015	OCT 22, 2019	U-501		

PATENT TERM EXTENSION AND NEW PATENTS -April 4, 2003  
 DOCKET NUMBER \*95S-0117  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD> 076061 001	PERGOLIDE MESYLATE;PERGOLIDE MESYLATE				PC	MAY 31, 2003
>ADD> 076061 002	PERGOLIDE MESYLATE;PERGOLIDE MESYLATE				PC	MAY 31, 2003
>ADD> 076061 003	PERGOLIDE MESYLATE;PERGOLIDE MESYLATE				PC	MAY 31, 2003
>ADD> 021438 001	PROPRANOLOL HYDROCHLORIDE; INNOPRAN XL	6500454	DEC 31, 2022		NP	MAR 12, 2006
>ADD> 021438 002	PROPRANOLOL HYDROCHLORIDE; INNOPRAN XL	6500454	DEC 31, 2022		NP	MAR 12, 2006
>ADD> 020903 001	RIBAVIRIN;REBETOL	6524570	NOV 01, 2016	U-499		
>ADD>		6524570*PED	MAY 01, 2017	U-499		
>ADD> 021071 002	ROSIGLITAZONE MALEATE;AVANDIA				I-384	FEB 27, 2006
>ADD> 021071 003	ROSIGLITAZONE MALEATE;AVANDIA				I-384	FEB 27, 2006
>ADD> 021071 004	ROSIGLITAZONE MALEATE;AVANDIA				I-384	FEB 27, 2006
>ADD> 019414 001	RUBIDIUM CHLORIDE RB-82;CARDIOGEN-82	4562829	MAY 01, 2004	U-503		
>ADD> 019839 001	SERTRALINE HYDROCHLORIDE; ZOLOFT				I-261	FEB 07, 2006
>ADD> 019839 002	SERTRALINE HYDROCHLORIDE; ZOLOFT				I-261	FEB 07, 2006
>ADD> 019839 003	SERTRALINE HYDROCHLORIDE; ZOLOFT				I-261	FEB 07, 2006
>ADD> 019839 004	SERTRALINE HYDROCHLORIDE; ZOLOFT				I-261	FEB 07, 2006
>ADD> 019839 005	SERTRALINE HYDROCHLORIDE; ZOLOFT				I-261	FEB 07, 2006
>ADD> 020990 001	SERTRALINE HYDROCHLORIDE; ZOLOFT				I-261	FEB 07, 2006
020926 001	SEVELAMER HYDROCHLORIDE; RENAGEL	6509013	AUG 13, 2013			
021179 001	SEVELAMER HYDROCHLORIDE; RENAGEL	6509013	AUG 13, 2013			
021179 002	SEVELAMER HYDROCHLORIDE; RENAGEL	6509013	AUG 13, 2013			
020280 007	SOMATROPIN RECOMBINANT; GENOTROPIN				ODE	OCT 31, 2004
020280 001	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
020280 002	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
020280 003	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
020280 005	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
020280 008	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
020280 009	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
020280 010	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
020280 011	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
020280 012	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
020280 013	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVAT				ODE	OCT 31, 2004
>ADD> 020749 001	TERBINAFINE HYDROCHLORIDE; LAMISIL	6121314	MAY 18, 2012	U-502		
>ADD> 021124 001	TERBINAFINE HYDROCHLORIDE; LAMISIL AT	6121314	MAY 18, 2012	U-504		
>ADD> 020489 001	TESTOSTERONE; ANDRODERM	4863970	NOV 14, 2006			
>ADD>		4983395	NOV 12, 2007			
>ADD>		5152997	DEC 11, 2010			
>ADD>		5164190	DEC 11, 2010			
>ADD>		4849224	NOV 12, 2007			
>ADD>		4855294	SEP 06, 2008			
>ADD> 020489 002	TESTOSTERONE; ANDRODERM	4849224	NOV 12, 2007			
>ADD>		4855294	SEP 06, 2008			
>ADD>		4863970	NOV 14, 2006			
>ADD>		4983395	NOV 12, 2007			
>ADD>		5152997	DEC 11, 2010			
>ADD>		5164190	DEC 11, 2010			



PATENT TERM EXTENSION AND NEW PATENTS -April 4, 2003  
 DOCKET NUMBER \*95S-0117  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021454 001	TESTOSTERONE; TESTIM				NP	OCT 31, 2005
>ADD>	021257 001				M-23	FEB 13, 2006
>ADD>	021108 001	6531141	MAR 07, 2020			
	020550 001				I-381	SEP 09, 2005
	020550 002				I-381	SEP 09, 2005
>ADD>	020699 001				I-261	FEB 11, 2006
>ADD>	020699 002				I-261	FEB 11, 2006
>ADD>	020699 003				I-261	FEB 11, 2006
>ADD>	020699 004				I-261	FEB 11, 2006
>ADD>	020552 001	4612008	SEP 16, 2003			
>ADD>		6146662	AUG 14, 2007	U-366		
>ADD>	020552 002	4612008	SEP 16, 2003			
>ADD>		6146662	AUG 14, 2007	U-366		